Xencor Inc.
03/09/2026 | Press release | Distributed by Public on 03/09/2026 14:01
Termination of Material Agreement (Form 8-K)
Item 1.02. Termination of a Material Definitive Agreement
On March 4, 2026, Xencor, Inc. (the "Company") received a notice of termination of an Amended and Restated Collaboration and License Agreement (the "Agreement"), effective as of June 1, 2024, with Genentech, Inc. ("GNE") and F. Hoffmann-La Roche Ltd ("Roche" and, GNE and Roche, collectively, "Genentech"), pursuant to which Genentech has elected to terminate the Agreement in its entirety for convenience. The effective date of the termination of the Agreement is September 4, 2026. Roche had previously announced, in connection with the reporting of its 2024 financial results in January 2025, that it removed efbalropendekin alfa, an engineered cytokine-Fc fusion protein and the sole active collaboration product under the Agreement, from its development pipeline, and the Company has expected Genentech's administrative termination of the Agreement.
During the first half of 2024, the Company ceased all cost-sharing development activities by electing to opt-out of co-development under the Agreement. Genentech assumed sole responsibility for all clinical, regulatory and commercial activities for certain collaboration products, including efbalropendekin alfa.
Xencor Inc. published this content on March 09, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on March 09, 2026 at 20:02 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]